Vertex Pharmaceuticals (VRTX) ended the recent trading session at $407.90, demonstrating a -1.05% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...

Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 10 years by 1.56% on an annualized basis producing an average annual return of 14.01%. Currently, Vertex Pharmaceuticals ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best biotech stocks to buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) participated in the Bank of America Global Healthcare ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...